ArticleChemical biology & drug design2026
Tyrosinase Inhibitors With Enhanced Potency in Mammalian and Vertebrate Models, N-(2-Mercaptoethyl)benzamide Derivatives: Design, Synthesis, and Evaluation.
Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Retaining structural features that allow 2-mercaptomethylbenzimidazole compounds to function as Cu(II) chelators, N-(2-mercaptoethyl)benzamide (NMEB) derivatives 1a-1m were designed, synthesized, and assessed for their potential as Cu(II) chelators. Derivative 1m inhibited mushroom tyrosinase (mTYR) activity twice as potently as kojic acid (KA) in the presence of l-DOPA. The mechanisms by which three derivatives, including 1m, inhibit mTYR were elucidated through kinetic studies. Interestingly, all NMEB derivatives suppressed melanogenesis more potently than KA in B16F10 cells, significantly reducing melanin production in a concentration-dependent manner. NMEB derivatives also inhibited cellular TYR activity in keeping with their melanogenesis inhibition, indicating B16F10 cellular TYR inhibition to be the primary mechanism. Moreover, among these derivatives, 1a inhibited zebrafish larval pigmentation hundreds of times more potently than KA. In mammalian cells and zebrafish larvae, NMEB derivatives showed even higher TYR-inhibitory or antimelanogenesis potency than mushrooms. Due to differences in the amino acid sequence and location of TYRs, NMEB derivatives appear to differ in their inhibition of TYR activity and melanin production in different species. This study points out limitations in the development of novel TYR inhibitors based on mTYR inhibition results and provides fundamental data supporting their development as novel skin-lightening agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.